The global vitamin D testing market size was estimated at USD 498.1 million in 2016. Global rise in geriatric population coupled with increase in chronic illnesses, such as type 2 diabetes, kidney disease, Crohn's disease, and celiac disease, is anticipated to drive the growth of the market.
The group of people at high risk of developing vitamin D deficiency includes pregnant & breast feeding women, teenagers, infants, and children under 5 years of age. This also includes people above 65 years, individuals who have low or no sun exposure, and darker skinned people.
U.S. vitamin D testing market by type of test, 2014 - 2025 (USD Million)
Furthermore, ongoing R&D activities, approval & commercialization of new tests, geographical expansion, and several government initiatives are likely to boost market growth during the forecast period. For instance, in the UK, various initiatives are underway to increase awareness about regular health screening amongst the low-income group, and they are likely to get free supplements through Healthy Start scheme. As per the American Osteopathic Association, nearly 1 billion people around the world have vitamin D deficiency. Hence, high incidence and availability of screening tests are likely to drive the market during the forecast period.
Two types of tests are used to measure the level of Vitamin D in the body, namely the 25 –Hydroxy Vitamin D (25 (OH)D; Calcifediol) and 1, 25-Dihydroxy Vitamin D (Calcitriol); based on which, the vitamin D testing market has been segmented into two parts.
In 2016, the 25 (OH)D test segment accounted for maximum market share and is expected to witness strong growth during the forecast period. This can be attributed to the availability of several products, recent commercialization, and the ability of the test to detect bone malfunctions accurately. For instance, in January 2015, Beckman Coulter Diagnostics received 510(k) clearance from the U.S.FDA for Access 25(OH) Vitamin D Total assay
Global vitamin D testing market by type of test, 2016 (%)
Due to a lesser number of companies providing 1,25 Dihydroxy Vitamin D test, this segment accounted for a lower share in 2016 as compared to 25 (OH)D test. Furthermore, due to its shorter half-life compared to 25 (OH)D, most physicians prefer using 25 (OH)D test in order to assess the level of Vitamin D in patients.
In June 2014, DiaSorin launched LIAISON XL assay outside the U.S. for quantitative determination of 1,25 Di-hydroxy Vitamin D level in human serum and plasma. This new assay is based on CLIA technology and is expected to further increase demand during the next few years.
North America dominated the global market, accounting for around 60% of the total market in 2016. This can be attributed to high awareness about regular screening, local presence of major players, and availability of several commercialized products in this region.
Asia Pacific was the fastest-growing region during the forecast period from 2017 to 2025, owing to commercialization of tests in Japan and China, growing demand in other emerging countries, such as India, and increasing expenditure on healthcare.
In July 2016, DiaSorin launched its CLIA 25 OH Vitamin D test in Japan after receiving approval of the reimbursement code from the Japanese authorities. Japan has about 13 million patients suffering from osteoporosis who will benefit from the test.
Germany, France, and Italy are the key markets in Europe, and Germany dominated in 2016. However, Spain, UK, and Switzerland are the emerging countries in this region. Good healthcare infrastructure, easy availability of products, high healthcare expenditure, and local presence of major players are the key factors driving demand.
Entry of various players in the market increases competition. Some of the major players are Abbott Laboratories; Danaher Corporation; F. Hoffmann-La Roche Ltd; Siemens Corporation, Quest Diagnostics, Inc.; bioMérieux SA; and DiaSorin S.p.A.
Product development and commercialization along with geographical penetration are key strategies deployed by market players to remain competitive. For instance, in November 2014, Roche announced an investment of CHF 450 million to build a new diagnostics equipment manufacturing facility in China. The facility is expected to commence operations by 2018. Hence, through this manufacturing site, Roche is likely to capture the diagnostics market in China as well as Asia Pacific. Furthermore, in September 2013, bioMerieux launched its new assay in Europe namely VIDAS 25 OH Vitamin D Total.
Attribute |
Details |
Base year for estimation |
2016 |
Actual estimates/Historical data |
2014 - 2016 |
Forecast period |
2017 - 2025 |
Market representation |
Revenue in USD Million and CAGR from 2017 to 2025 |
Regional scope |
North America, Europe, Asia Pacific, Central & South America, Middle East & Africa |
Country scope |
U.S., Canada, Germany, U.K., China, Brazil, Mexico, South Africa |
Report coverage |
Revenue forecast, competitive landscape, growth factors and trends |
15% free customization scope (equivalent to 5 analyst working days) |
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at global, regional, & country levels and provides an analysis on industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global vitamin D testing market on the basis of type of test and region:
Type of Test Outlook (Revenue, USD Million, 2014 - 2025)
25-Hydroxy Vitamin D Test
1, 25-Dihydroxy Vitamin D Test
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
The U.S.
Canada
Europe
Germany
The U.K.
Asia Pacific
China
Central & South America
Brazil
Middle East & Africa
South Africa
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.